I den fjerde undersøgelse blev forbruget af fluticason (et binyre - barkhormon) mindsket mere hos patienter, der fik Xolair, end hos dem, der fik placebo.
In the fourth study, there was a greater reduction in use of fluticasone (a corticosteroid) in the patients taking Xolair than in those taking placebo.